Validation of a Prediction Model for Inadequate Bowel Preparation
Validation of a Prediction Model for Inadequate Bowel Preparation Before Colonoscopy Based on a Systematic Review and Meta-analysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xingshun Qi
- Phone Number: 18909881019
- Email: xingshunqi@126.com
Study Contact Backup
- Name: Weiyi Wang
- Phone Number: 13019441024
- Email: 373302698@qq.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 110840
- Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult patients (age is ≥18 years old);
- patients undergoing colonoscopy;
- written informed consent.
Exclusion Criteria:
- patients undergoing emergent colonoscopy;
- patients with major psychiatric disorders;
- pregnant or breast feeding patients;
- patients with contraindications for colonoscopy (e.g., heart failure, renal insufficiency);
- patients suspected to have intestinal obstruction, stenosis or perforation;
- poor compliance with the bowel preparation protocol (poor compliance is indicated if the dose of medication was < 75% of the prescribed dose;
- incomplete colonoscopy because of other circumstances apart from inadequate cleansing
- patients previously enrolled in this study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing colonoscopy in General Hospital of Northern Theater Command
Patients were informed to eat semi-liquid and non-slag diet for breakfast and lunch and full-liquid diet for dinner on the day before colonoscopy, and be fasting on the day of colonoscopy.
A split-dose 3 L PEG regimen was used for all patients.
|
Patients use purgative for bowel cleansing before colonoscopy.
|
|
Patients undergoing colonoscopy in First Affiliated Hospital of China Medical University
Patients were informed to eat semi-liquid and non-slag diet for breakfast and lunch and full-liquid diet for dinner on the day before colonoscopy, and be fasting on the day of colonoscopy.
A split-dose 2 L PEG regimen was used for all patients.
|
Patients use purgative for bowel cleansing before colonoscopy.
|
|
Inpatients undergoing colonoscopy in Second Affiliated Hospital of Army Medical University
We retrospectively collect data of inpatients undergoing colonoscopy.
Patients were informed to eat semi-liquid and non-slag diet for breakfast and lunch and full-liquid diet for dinner on the day before colonoscopy, and be fasting on the day of colonoscopy.
A full-dose 3 L PEG regimen was used for all patients.
|
Patients use purgative for bowel cleansing before colonoscopy.
|
|
Patients undergoing colonoscopy in No. 960 Hospital
Patients were informed to eat semi-liquid and non-slag diet for breakfast and lunch and full-liquid diet for dinner on the day before colonoscopy, and be fasting on the day of colonoscopy.
Split-dose 3 L PEG, sodium phosphate or sodium picosulfate regimen were used according to the doctor's advice.
|
Patients use purgative for bowel cleansing before colonoscopy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of bowel preparation
Time Frame: During the procedure of colonoscopy
|
A total BBPS score ≥6 with BBPS score ≥2 for each colon segment was considered to have adequate bowel preparation.
Each segment of the colon is scored from 0 to 3, with higher scores indicating superior cleansing, and summed for a total score that can range from 0 to 9.
|
During the procedure of colonoscopy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adenoma and/or polyp detection rate
Time Frame: During the procedure of colonoscopy
|
Proportion of patients with at least one adenoma and/or polyp detected during colonoscopy
|
During the procedure of colonoscopy
|
|
Number of polyps and/or adenomas
Time Frame: During the procedure of colonoscopy
|
Number of polyps and/or adenomas detected during colonoscopy
|
During the procedure of colonoscopy
|
|
Adverse events
Time Frame: Before the procedure of colonoscopy
|
Incidence of abdominal pain, bloating, nausea/vomiting after intake of purgative.
|
Before the procedure of colonoscopy
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xingshun Qi, Department of Gastroenterology, General Hospital of Northern Theater Command
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- V-PMIBP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.